Nasdaq cprx.
The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 12.30x, while the 36-month beta value is 1.08.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, Inc ...The latest price target for . Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on August 22, 2023.The analyst firm set a price target for $27.00 expecting CPRX to rise to ...See the latest Catalyst Pharmaceuticals Inc stock price (CPRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Mar 16, 2023 · Catalyst Pharmaceuticals, Inc. CPRX reported earnings of 22 cents per share for the fourth quarter of 2022, marginally beating the Zacks Consensus Estimate of 21 cents. Earnings were also higher ... Mar 31, 2020 · Find the latest Revenue & EPS data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.
Analyst Future Growth Forecasts. Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs …The $210.13 million and $294.89 million estimates for the current and next fiscal years indicate changes of +49.2% and +40.3%, respectively. Catalyst reported revenues of $57.24 million in the ...(CPRX). NASDAQ: CPRX · IEX Real-Time Price · USD. Add to Watchlist. 14.06. +0.20 (1.44%). At close: Nov 24, 2023, 1:00 PM. 13.82. -0.24 (-1.71%). After-hours: ...
Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known ...
CORAL GABLES, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the second quarter …14 jam yang lalu ... Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and ...Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high ...Catalyst Pharmaceuticals has a total shareholder equity of $348.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $413.2M and $64.7M respectively. Catalyst Pharmaceuticals's EBIT is $75.9M making its interest coverage ratio -13.9. It has cash and short-term investments of $121.0M.The stock of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has increased by 5.94 when compared to last closing price of 12.63.Despite this, the company has seen a gain of 4.12% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results.
Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine).
CPRX Catalyst Pharmaceuticals, Inc. Stock Price & Overview 17.97K followers $14.82 0.39 ( +2.70%) 4:00 PM 12/01/23 NASDAQ | $USD | Post-Market: $14.85 +0.03 (+0.20%) 7:59 PM Summary Ratings...
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.Sep 21, 2022 · The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ... Catalyst Pharmaceuticals has a total shareholder equity of $348.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $413.2M and $64.7M respectively. Catalyst Pharmaceuticals's EBIT is $75.9M making its interest coverage ratio -13.9. It has cash and short-term investments of $121.0M.You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart. NasdaqCM:CPRX Earnings and Revenue History July 30th 2021Overview News Catalyst Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data 26.66 ( 11/24/23) EPS (TTM) $0.53 Market Cap $1.50 B CPRX N/A N/A Short Interest ()...
Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 70% over the last three months. Given the company's impressive performance, we ...Jan 24, 2023 · January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ... Overview News Catalyst Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data 26.66 ( 11/24/23) EPS (TTM) $0.53 Market Cap $1.50 B CPRX N/A N/A Short Interest ()...Its revenues for 2022 advanced over 2021 at an advanced 59% clip. During Catalyst's Q4, 2022 earnings call (the "Call") CEO McEnany forecast its 2023 revenues in a $245-$255 million range. Taking ...CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...
Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...
CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...Apr 17, 2023 · Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was founded in 2002 and generated its first profits in 2019. The 10-year results are summarized below. The 10-year results are summarized below. CPRX ... (Nasdaq: CPRX) announced today that it has entered into definitive agreements to sell (i) 4.0 million shares of the Company's common stock, and (ii) common ...There are 542 funds or institutions reporting positions in Catalyst Pharmaceuticals. This is an increase of 82 owner (s) or 17.83%. Average portfolio weight of all funds dedicated to US:CPRX is 0. ...Catalyst Pharmaceutical (CPRX) closed at $15.25 in the latest trading session, marking a -1.74% move from the prior day. This move was narrower than the S&P 500's daily loss of 2%. Meanwhile, the ...Long trade in CPRX CPRX is the #1 stock in the biotech group by almost every metric. The table on the chart shows its ranking out of all 795 biotech stocks by 3 metrics from IBD's MarketSmith. Sales and earnings are surging and the rate at which both are growing has increased in each of the last 4 quarters. The stoCPRX is the #1 stock in the ...Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Earnings Report Date | Nasdaq. Created with Sketch. *The upcoming earnings date is derived from an algorithm based on a company's historical ...Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...
CORAL GABLES, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update.
This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The ...
(NASDAQ: CPRX) Catalyst Pharmaceuticals's market cap is $1.37B, as of Nov 8, 2023. Market cap (market capitalization) is the total market value of a publicly …Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. The stock’s 50-day simple moving ...CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours... Catalyst Pharmaceuticals CPRX has reached a settlement with Jacobus Pharmaceutical Company, Inc. and PANTHERx Rare LLC, with regard to the ongoing patent infringement litigation over its sole ...CPRX Catalyst Pharmaceuticals, Inc. Stock Price & Overview 17.97K followers $14.82 0.39 ( +2.70%) 4:00 PM 12/01/23 NASDAQ | $USD | Post-Market: $14.85 +0.03 (+0.20%) 7:59 PM Summary Ratings...Aug 2, 2023 · Fintel reports that on August 11, 2023, Cantor Fitzgerald maintained coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 52.12% Upside Crypto Sectors U.S. markets closed +26.83 +78.81 Russell 2000 +53.62(+2.96%) Crude Oil -1.58(-2.08%) Gold +34.50(+1.68%) Catalyst Pharmaceuticals, Inc. (CPRX) NasdaqCM - NasdaqCM Real Time... Nov 30, 2023 · NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News & Analysis Should You Buy or Sell Catalyst Pharmaceuticals Stock? Get The Latest CPRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Should You Buy or Sell Catalyst Pharmaceuticals Stock? The latest price target for Catalyst Pharmaceuticals ( NASDAQ: CPRX) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 27.00 expecting CPRX to ...Deerfield Management was the largest stakeholder in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, holding 4.9 million shares worth $62.8 million. In total, 18 funds were long ...Catalyst Pharmaceuticals (NASDAQ:CPRX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business?We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, …For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...
Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 514% over five years. This just goes to show the value creation that some businesses can achieve.The $210.13 million and $245.56 million estimates for the current and next fiscal years indicate changes of +49.2% and +16.9%, respectively. Last Reported Results and Surprise History. Catalyst ...Nov 30, 2023 · The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has plunged by -1.13 when compared to previous closing price of 14.21, but the company has seen a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales […] Instagram:https://instagram. how can i make money from forex tradingtrade ariestop rated international mutual fundswhere to buy pink sheet stocks Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, ...CORAL GABLES, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the second quarter … most expensive house in kentuckybeyond meat stoc Real time Catalyst Pharmaceuticals (CPRX) stock price quote, stock graph, news & analysis. Starbucks’ (NASDAQ:SBUX) 100% Return Could Be Coming At A Cost Dec 2, 2020 Tesla Inc., (NASDAQ:TSLA) is Getting Stronger, and it may be Time to Reevaluate Feb 11, 2022 Calculating The Fair Value ... swlf Allspring Global Investments Holdings LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 21.7% in the second quarter, according to the company in its most ...Find the latest dividend history for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Feb 28, 2023 · Catalyst Pharmaceuticals (NASDAQ:CPRX) is another biotech that has performed strongly over the past twelve months. During this timeframe, shares have nearly doubled in price. During this timeframe ...